Inspire therapy—a hypoglossal nerve stimulation implant—has been FDA-approved for more than 11 years, with over 100,000 patients treated across the US, Europe, and Asia. Ruchir Patel, Inspire’s senior medical director, says data show reductions in daytime sleepiness, a 79 percent drop in sleep apnea severity, and a 90 percent reduction in snoring. Early US data report average nightly usage of more than 6.5 hours. “This is an exciting time because there are more treatment options available than…

![[CITYPNG.COM]White Google Play PlayStore Logo – 1500×1500](https://startupnews.fyi/wp-content/uploads/2025/08/CITYPNG.COMWhite-Google-Play-PlayStore-Logo-1500x1500-1-630x630.png)